Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EADO 2020 | Real-world use of t-vec in unresectable stage IIIB-IvM1a melanoma

Alexander van Akkooi • 14 Oct 2020
EADO 2020
Melanoma Skin Cancer Talimogene laherparepvec

Alexander van Akkooi, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses a retrospective study that investigated the clinical use of talimogene laherparepvec (t-vec) in patients with unresectable stage IIIB-IvM1a melanoma in four European countries. This is interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Alexander van Akkooi

1:43
Real-world analysis of T-VEC for melanoma
Alexander van Akkooi • 19 Apr 2021
2:27
Serum NSE levels as a biomarker in MCC
Alexander van Akkooi • 19 Apr 2021
2:38
Sentinel node tumor burden for prognostication in melanoma
Alexander van Akkooi • 19 Apr 2021
2:41
Immunotherapies for satellite or ITM melanoma
Alexander van Akkooi • 19 Apr 2021

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals